Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community

SAN DIEGO, May 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC). Arena will present...

from PR Newswire: https://prn.to/2WJaDJL